The study, published in Nature Aging, found that FTL1 builds up in the hippocampus, the brain’s memory center, as mice get older. Too much of this protein disrupts brain function. Older mice with elevated FTL1 performed poorly on memory tasks. To confirm the link, scientists boosted FTL1 in younger mice.

To confirm the link, scientists boosted FTL1 in younger mice. These healthy mice quickly developed memory problems similar to older ones. But when scientists lowered FTL1 levels in aging mice, something remarkable happened: their memory improved to the level of much younger mice.

How FTL1 Affects the Brain

FTL1 helps store iron inside cells, but when it builds up in the brain, it disrupts how neurons generate and use energy. Neurons need energy to build and maintain connections, which are the pathways for learning and memory.

When FTL1 levels rise, neurons lose power. They cannot store information as effectively, leading to forgetfulness. Scientists also observed that older mice with high FTL1 had fewer connections between brain cells.

The team used advanced tools, including viruses and genetic methods, to change FTL1 levels. They then put mice through memory and learning challenges, such as solving mazes and recognizing objects. After reducing FTL1, older mice performed almost as well as young mice, proving that brain function could be restored.

The research also tested metabolism. Researchers discovered that when FTL1 levels rise, neurons struggle to produce enough energy. When they added NADH, a compound that helps with cell energy, memory problems improved. This suggests that targeting brain energy systems could be another way to help with memory loss reversal.

What This Means for Humans

While the results are exciting, the research is still at an early stage. The experiments were done only in male mice, and the human brain is far more complex. A treatment that works in mice may not work the same way in people.

Currently, there are no safe drugs that directly reduce FTL1 in humans. The methods used in the study involved genetic tools, not medicines. Researchers warn that it could take years before this discovery leads to new therapies.

Still, the findings are important because they focus on normal, age-related memory decline, not just diseases like Alzheimer’s. Almost everyone experiences some memory loss with age. By targeting FTL1, scientists may one day find a way to help a much larger group of people.

In the United States, between six and 12 million people over 65 live with mild cognitive impairment, a condition that often leads to dementia. About one-third of them develop Alzheimer’s within five years. For these individuals, new options for memory loss reversal could make a huge difference.

A New Direction in Brain Research

For decades, dementia research has centered on proteins like beta-amyloid and tau, which form clumps and tangles in the brain. The UCSF study adds a new angle by showing that iron-related proteins and energy systems may also be key to memory decline.

By focusing on FTL1, scientists are opening doors to treatments that could help almost everyone as they grow older—not just those with Alzheimer’s disease.

[Source]

The post Scientists Find Way to Reverse Memory Loss in Mice appeared first on Medical Journal Daily.

The new testing system is currently undergoing trials in Cumbria and the North East of England, and health officials plan to extend its availability to the rest of the UK before the end of the year. If successful, it could offer lessons for healthcare systems worldwide, including the United States, where over 37 million adults live with diabetes and millions remain undiagnosed.

How the Test Works

PocDoc’s test is built around the HbA1c marker, widely recognized as the benchmark for identifying and tracking type 2 diabetes. HbA1c measures average blood glucose levels over the past two to three months, offering a reliable picture of long-term sugar control rather than just a single reading. To use the test, patients begin with a simple finger-prick to provide a small blood sample.

The sample is then applied to PocDoc’s patented microfluidic test cartridge, which is designed to capture and process the biomarker. Using the companion smartphone app, the cartridge is scanned, and results are generated in less than 10 minutes, eliminating the need for laboratory analysis.

By shifting screening away from clinics and into homes, pharmacies, and community spaces, the technology reflects a broader trend in digital health—giving individuals greater control and convenience in monitoring chronic conditions such as diabetes.

Why It Matters for Public Health

Type 2 diabetes is one of the most preventable chronic conditions, yet it continues to grow rapidly worldwide. In the UK, around 5.2 million people live with the disease, and another 1.3 million are undiagnosed. Treating diabetes and its complications costs the National Health Service (NHS) about £8.8 billion annually, nearly 10% of its total budget.

In the United States, the challenge is even greater. The Centers for Disease Control and Prevention (CDC) reports that diabetes costs the U.S. healthcare system $327 billion each year, with nearly $1 in every $4 healthcare dollars spent on treating the disease. Alarmingly, 96 million Americans are estimated to have prediabetes, but the majority do not know it.

For both the NHS and U.S. healthcare providers, earlier detection could significantly reduce long-term costs and complications. Lifestyle interventions, such as improved diet, exercise, and weight management, have been shown to reduce the risk of type 2 diabetes by nearly 50% if introduced early.

Professor Julia Newton from Health Innovation Northeast and North Cumbria highlighted this potential: “Type 2 diabetes can often be prevented or even reversed through early detection and lifestyle change. Making tests available at the touch of a button could be a game-changer.”

Implications for U.S. Healthcare

The United States faces unique challenges in managing diabetes. While annual screenings are recommended for high-risk groups, access remains uneven—particularly in rural areas, among uninsured populations, and in communities with limited primary care.

Smartphone-based testing could help bridge these gaps. With more than 85% of U.S. adults owning a smartphone, app-driven diagnostics could reach populations underserved by traditional healthcare. Pharmacies, employer wellness programs, and telehealth providers could integrate rapid HbA1c testing into their services, helping millions access earlier screenings.

That said, scaling such a system in the U.S. would require FDA approval, insurance integration, and careful oversight to ensure accuracy. The FDA has previously flagged risks with some health apps that failed to provide reliable alerts. Ensuring data security and equitable access will also be critical.

Still, experts believe that digital-first models could save billions annually by reducing hospitalizations, dialysis treatments, and cardiovascular emergencies linked to late-diagnosed diabetes.

The Future of At-Home Testing

The diabetes test is not PocDoc’s first foray into digital diagnostics. The company also launched a Healthy Heart Check, an at-home cholesterol and cardiovascular risk screening kit. Its success indicates a broader shift toward self-administered, technology-driven preventive care.

If the diabetes test proves successful in the UK, expansion into other markets could follow. For U.S. patients, this would mean faster access to critical health information and greater control over managing their risk factors.

As healthcare systems worldwide grapple with rising chronic disease costs, tools like the PocDoc test show how technology and preventive medicine can work hand-in-hand. Instead of waiting for symptoms to appear or results to trickle in from distant labs, patients could soon hold answers in the palm of their hand—literally.

[Source]

The post Diabetes Smartphone Test Could Diagnose Condition in Under 10 Minutes appeared first on Medical Journal Daily.

What is Vein of Galen Malformation?

In a person with Vein of Galen malformation (VOGM), arteries connect directly to veins deep in the brain without the normal network of capillaries in between. Without this slowing mechanism, blood rushes at high pressure into the brain’s deep veins, placing strain on the heart and affecting brain function.

The condition can cause a range of serious problems, including heart failure, a build-up of fluid in the brain (hydrocephalus), seizures, developmental delays, and sometimes bleeding within the brain. If left untreated, it carries a very high risk of death—some estimates put mortality at more than three-quarters of cases. Even when treated, the risks remain significant.

Most children diagnosed with VOGM undergo a less invasive treatment known as endovascular embolization. In this procedure, doctors insert a catheter—typically through the groin—and navigate it through the blood vessels until it reaches the abnormal connection in the brain. Special materials are then placed to block the abnormal connections. This technique has transformed survival rates and outcomes for many patients.

A Different Kind of Challenge

For Conor O’Rourke, a three-year-old from Liverpool, standard treatment was not enough. His VOGM was first picked up during a routine check, when a consultant spotted that the shape of his head seemed unusual. Further investigation confirmed the diagnosis—but his case would prove far from straightforward.

But surgeons discovered a major complication—his jugular veins were blocked. This prevented them from reaching the malformation via the normal route, leaving the swelling unchecked and causing damage to his brainstem and spinal cord.

Faced with no viable alternative, neurosurgeon Conor Mallucci and his team at Alder Hey Children’s Hospital designed a new approach. In March, they carried out what is believed to be the world’s first direct open-skull operation for this type of VOGM. By accessing the malformation directly through the skull, they were able to treat it successfully.

Conor’s recovery was described as remarkable. According to his surgical team, he is now “99 per cent cured” and doing well.

Why This Breakthrough Matters

This breakthrough offers hope for children with high-risk cases of Vein of Galen malformation, particularly those whose anatomy or blocked vessels make traditional embolization impossible. By creating an entirely new treatment pathway, it addresses situations where no viable options previously existed and survival chances were low.

Conor’s case also highlights the critical role of early detection—his diagnosis was made possible when an attentive doctor noticed subtle signs during a routine check-up, allowing intervention before further damage occurred.

Finally, it underlines the value of specialist expertise, as Alder Hey is one of only two centers in the UK equipped to carry out such complex pediatric neurosurgery.

Around the world, researchers are also looking at treating VOGM before a baby is born.

In the United States, specialists recently performed the first in-utero embolization, using ultrasound to guide a microcatheter into a fetus’s brain and place small coils to slow blood flow. The baby was delivered with improved heart function and no signs of brain injury. While still experimental, such procedures hint at the possibility of preventing damage before it starts.

The Road Ahead

Even with the best treatment, VOGM is a lifelong condition that requires careful follow-up. Children may need ongoing input from neurosurgeons, cardiologists, neurologists, and developmental specialists to monitor growth and learning.

Historical data from Great Ormond Street Hospital between 2003 and 2008 found that among children who survived treatment, 39% developed normally, 21% had mild developmental delays, and 18% had more significant challenges. These figures show why surgical advances like the one at Alder Hey could make such a difference—not just in saving lives, but in improving how those lives are lived.

[Source: 1,2]

The post World-First Surgery at Alder Hey Saves Toddler from Rare Vein of Galen Malformation appeared first on Medical Journal Daily.

Why Subtypes Matter

Autism is known for its complexity. Despite being highly heritable, with hundreds of genes linked to it, only about 20% of cases reveal a clear genetic cause. Until now, clinical diagnosis relied on broad categories based on social communication challenges and repetitive behaviors. These general classifications miss much of the diversity within the spectrum.

The new study, conducted by researchers at Princeton University and the Simons Foundation, breaks this down. By analyzing data from the SPARK cohort—tracking over 230 traits in children aged 4 to 18—the team used a statistical model to group individuals by shared characteristics and then mapped those to their genetic differences.

The Four Autism Subtypes

1. Social and Behavioral Challenges (37%)
   Children in this group had pronounced social communication difficulties and repetitive behaviors, along with conditions such as ADHD, anxiety, or depression. Despite these challenges, their developmental milestones—like walking and talking—were largely on track.
2. Mixed ASD with Developmental Delay (19%)
   These children showed developmental delays but had mixed levels of core autism traits. They were less likely to show psychiatric symptoms like anxiety or mood disorders.
3. Moderate Challenges (34%)
   This group showed less intense autism-related behaviors and achieved developmental milestones at typical ages. They also had a lower occurrence of additional psychiatric conditions.
4. Broadly Affected (10%)
   The most affected group had wide-ranging difficulties across development, behavior, and mental health, including delays and mood regulation issues. These classifications, though not comprehensive, represent the most clearly distinct clusters in this dataset. The subtypes were also validated in a second, independent group of autistic children.

Genetic Differences Reflect Clinical Profiles

Each subtype showed unique patterns of genetic variation. For example, the Broadly Affected group had the highest rate of damaging de novo mutations—those not inherited from parents. In contrast, the Mixed ASD group had more inherited rare variants. These differences suggest separate biological pathways leading to similar outward symptoms.

The study also revealed that the timing of gene activity varied between groups. In the Social and Behavioral Challenges subtype, mutations occurred in genes that become active after birth, possibly explaining why these children were diagnosed later and did not show developmental delays.

Toward Personalized Autism Care

Experts say the findings offer a starting point for more targeted diagnosis and intervention. “These are not just clinical labels,” says co-lead author Aviya Litman, “they are grounded in biology.” For families, knowing a child’s subtype could help guide expectations, support plans, and treatment choices.

While more work is needed—especially to include more diverse populations—the study provides a framework that could redefine autism care. “It’s a shift from trying to explain all of autism with one model,” says Natalie Sauerwald, co-lead author, “to recognizing multiple biological narratives.”

This research, part of a decade-long effort funded by the Simons Foundation and others, highlights the value of integrating genetics, psychology, and data science. As researchers apply this model to other complex conditions, it opens new possibilities for understanding—and treating—human diversity in health.

[Source]

The post Researchers Identify Four Autism Subtypes with Distinct Genetic Profiles appeared first on Medical Journal Daily.

Now, scientists at the Peter Doherty Institute in Melbourne have achieved something that was previously thought impossible: they’ve used mRNA-loaded lipid nanoparticles to enter those elusive cells and force the dormant virus into the open. The technique, described in a June 2025 paper published in Nature Communications, may mark a major turning point in the decades-long effort to cure HIV.

LNP X, the new delivery system developed by the researchers, builds on lipid nanoparticle technology used in COVID-19 vaccines but with a crucial upgrade. Unlike earlier formulations, this version is able to enter resting CD4+ T cells—an especially challenging target—and deliver mRNA without triggering cell activation or causing harm.

Once inside, the mRNA instructs the cells to produce HIV’s Tat protein—a viral activator that wakes the virus up, making it visible to the immune system or future treatments.

A Hidden Target, Now Within Reach

Until now, delivering anything into resting T cells was nearly impossible. These cells are designed to stay quiet and resist manipulation. Traditional nanoparticles were simply ignored. But LNP X changes the game.

In lab experiments using blood samples from people living with HIV, the LNP X-mRNA package triggered a measurable increase in HIV gene activity. Dormant virus, once undetectable, was reactivated inside the cells. That doesn’t eliminate HIV from the body—but it makes it visible, which is the first essential step toward destroying it.

Dr. Paula Cevaal, co-lead author of the study, explained that they repeated the tests multiple times, and each time the results were consistent and significantly better than anything they had previously observed.

The research also shows that LNP X can carry more than just Tat. It successfully delivered CRISPR-based gene activators as well, opening the door to future strategies that fine-tune both viral and host cell behavior.

Why This Matters

For over a decade, scientists have floated the idea of a “shock and kill” strategy—activate latent HIV and then destroy the infected cells. But the “shock” part has always been unreliable. LNP X could be the first tool that delivers this activation step with precision and efficiency.

The technology is still in its early stages. The current results are limited to cell samples tested in a lab. Scientists will need to develop strategies to actually kill the infected cells afterward.

Researchers, including co-senior author Dr. Michael Roche, believe the platform could have broader applications beyond HIV. He noted that resting CD4+ T cells play roles in various conditions such as cancer, autoimmune diseases, and immune suppression. If these cells can now be targeted with mRNA or CRISPR-based therapies, it could open the door to a wide range of new treatment possibilities.

Even a small fraction—such as 10%—could potentially be enough to reignite the infection. Despite this uncertainty, he acknowledged that the findings represent a major step forward.

There is no silver bullet for HIV. But this breakthrough—delivering mRNA directly into the virus’s safest hiding place—may finally remove one of the biggest obstacles to a cure. With further development, the approach could transform how we treat not just HIV, but other diseases tied to immune cell behavior.

[Source]

The post Scientists Use mRNA Nanoparticles to Force Hidden HIV Out of White Blood Cells appeared first on Medical Journal Daily.

A team of researchers at the University of California, Davis has developed a new drug called JRT, which is chemically similar to LSD, the well-known psychedelic. But unlike LSD, JRT doesn’t cause hallucinations. It appears to stimulate brain repair without triggering hallucinations—offering a new tool for conditions that have long resisted effective treatment.

This breakthrough was recently published in the Proceedings of the National Academy of Sciences (PNAS).

The Challenge of Treating Schizophrenia’s Cognitive Core

While standard antipsychotic drugs are effective in treating the “louder” symptoms of schizophrenia—hallucinations, delusional thinking, and jumbled speech, the more subtle impairments, such as lack of motivation, memory issues, and emotional flatness, persist.

Medications like clozapine may help a fraction of patients, but they bring significant side effects and are rarely used as first-line options.

There has been little progress in reversing the actual brain changes that accompany schizophrenia, particularly shrinking connections between neurons in the prefrontal cortex. That’s where JRT steps in.

The researchers achieved something strikingly simple yet powerful: they switched the position of two atoms in LSD’s molecular scaffold. This minor rearrangement gave birth to JRT—a molecule with nearly identical shape and weight but drastically different behavior in the brain.

To put it plainly, it’s like taking the engine of a race car and repurposing it for a hybrid sedan: you retain the performance engine, but leave behind the wild ride.

Neuroplasticity Without the High

JRT belongs to a class of molecules known as psychoplastogens—compounds that help neurons grow, reconnect, and adapt. But while most known psychoplastogens (like psilocybin or LSD) also activate brain regions tied to hallucinations, JRT was designed to avoid those pathways.

In lab tests, JRT boosted the growth of dendritic spines—tiny structures that enable neurons to communicate—by nearly 46%. These effects were concentrated in the prefrontal cortex, a brain area crucial for decision-making and mood regulation.

Anecdotally, one UC Davis researcher likened JRT to “a fertilizer for the brain’s communication highways,” minus the sensory detours.

So far, JRT has only been tested in mice—but the results are encouraging. In behavioral tests, mice treated with JRT showed reduced depression-like behavior and improved cognitive flexibility, without signs of the psychedelic-like behaviors typically triggered by LSD.

Most notably, JRT was about 100 times more potent than ketamine—a fast-acting antidepressant—in producing these therapeutic effects, and did so at significantly lower doses. It also did not ramp up the expression of genes associated with schizophrenia, a common problem with hallucinogenic compounds.

The Broader Promise of Non-Hallucinogenic Psychedelics

JRT isn’t just a one-off discovery—it’s part of a growing trend to divorce psychedelics from their hallucinatory effects. Researchers are increasingly interested in molecules that harness the regenerative and anti-inflammatory power of psychedelics, while avoiding the risks that come with altered perception.

This is especially important for psychiatric populations often excluded from clinical trials involving psychedelics, such as those with schizophrenia, bipolar disorder, or a strong family history of psychosis.

JRT is still far from pharmacy shelves. The compound took nearly five years and 12 separate chemical steps to synthesize. Researchers are now working to improve its manufacturability and are testing its effects in other disease models, including neurodegenerative conditions like Alzheimer’s.

Clinical trials in humans are still some distance away, but the foundational work opens the door for a new generation of precision psychedelic medicine.

[Source]

The post Scientists Create LSD-Like Drug That Heals the Brain Without Causing Hallucinations appeared first on Medical Journal Daily.

The patient, KJ Muldoon, was diagnosed shortly after birth with carbamoyl phosphate synthetase 1 (CPS1) deficiency, a urea cycle disorder that disrupts the body’s ability to eliminate ammonia. The condition, which affects about 1 in 1.3 million newborns, can cause rapid and irreversible brain damage if untreated.

A Precision-Driven Approach to a Rare Mutation

CPS1 deficiency is caused by mutations in the CPS1 gene, and in KJ’s case, the mutation was both extremely rare and severe. The standard approach to treatment involves strict dietary control, ammonia-scavenging drugs, and often liver transplantation. However, the underlying gene defect remains unaddressed by these treatments.

Researchers at the University of Pennsylvania and Children’s Hospital of Philadelphia developed a novel approach: base editing, a refined version of CRISPR that enables the precise conversion of a single DNA base into another.

This method significantly reduces the risk of unwanted edits or large-scale genetic disruptions, a limitation of earlier CRISPR systems.

The therapy was designed specifically for KJ’s unique mutation, requiring a rapid and collaborative development effort between academic labs, regulatory agencies, and biotech companies. The gene-editing components were delivered to the liver using lipid nanoparticles—an established delivery platform also used in mRNA vaccines.

Condensed Timeline Reflects Technical Agility

Typically, gene therapies take years to develop, test, and approve. In this case, the therapy was designed, validated in lab models, and prepared for clinical use in just six months.

That timeline was made possible through emergency-use regulatory flexibility granted by the U.S. Food and Drug Administration (FDA), as well as public-private partnerships that provided key resources at cost or through in-kind support.

The first low-dose infusion of the therapy was administered in early 2024. The treatment was monitored closely for efficacy and safety, with a focus on metabolic stability and ammonia levels. Within two weeks, clinicians observed an increase in KJ’s protein tolerance, an indirect marker of restored urea cycle function.

Following two additional doses, doctors reported sustained metabolic stability, reduced need for supportive medications, and no observed adverse effects related to the editing process.

Scientific and Regulatory Significance

The successful case demonstrates the clinical viability of “n=1” gene-editing therapies—treatments developed for a single patient with a specific mutation.

According to Dr. Kiran Musunuru, the lead researcher and a professor of cardiovascular medicine at Penn, the base-editing construct corrected the pathogenic variant with minimal off-target activity in lab testing, and the child’s clinical response aligns with that prediction.

This approach may serve as a blueprint for treating other ultra-rare genetic disorders. The core components of base editing can be reused, with the targeting element customized for each patient’s specific mutation. This modularity could dramatically reduce the development time and cost for future therapies.

Regulators, including FDA official Dr. Peter Marks, have expressed cautious optimism. Marks described the case as “proof-of-concept” for personalized genomic medicine, while emphasizing the need for long-term monitoring and further validation before broader adoption.

The Road Ahead

KJ remains under medical supervision but is showing normal development for his age. If progress continues, he may soon be discharged from the hospital—an outcome rarely seen in severe cases of CPS1 deficiency without a liver transplant.

While this therapy was created specifically for one patient and will not be used for others, it highlights a path forward for the estimated 30 million Americans affected by rare genetic conditions.

Researchers involved in the case stress that such interventions must be backed by rigorous preclinical data and clear ethical oversight. But for now, KJ’s case represents a tangible milestone: the merging of CRISPR science, clinical urgency, and regulatory flexibility to deliver a treatment that would not have been possible just a few years ago.

[Source: 1,2]

The post CRISPR-Based Gene Editing Saves Infant with Rare Metabolic Disorder in World First appeared first on Medical Journal Daily.

The breakthrough, led by Professor Per-Ola Carlsson, offers hope for a safer, more sustainable therapy that targets the root cause of the disease.

What’s Changed—and Why It Matters

Transplanting insulin-producing cells isn’t new. The problem has always been the immune system: it sees donor cells as foreign invaders and attacks. Until now, the only way around this was lifelong immunosuppression—medications that dampen the immune response but increase risks for infections, cancers, and other complications.

Carlsson and his team have flipped the script. Instead of weakening the immune system, they’ve engineered the donor cells to avoid triggering it altogether. These modified cells are engineered to be “hypoimmune,” meaning they don’t trigger the body’s usual immune alarms. Instead of being flagged and attacked, they remain undetected, allowing them to function without interference.

It’s a clever reframe of the problem, shifting the focus from managing the immune response to eliminating the cause of it.

Inside the Breakthrough: How the Cells Stay Hidden

The modified cells have been altered in three key genetic ways, allowing them to operate “under the radar,” as Carlsson puts it. The early results are promising. Since the trial began in December, the transplanted cells have remained active and stable, continuing to produce insulin with no evidence of immune rejection.

That’s a stark contrast to earlier efforts, where conventional donor cells would be attacked and fail within weeks. The genetic modifications appear to prevent that decline, marking a significant advancement in cell-based therapies for diabetes.

From Trial to Treatment of Type 1 Diabetes Cell Transplant

This initial study is designed to track long-term safety over a 15-year period. But more trials could begin sooner, especially as the team works to apply the same genetic tweaks to stem cells. That step would open the door to scalable production—allowing millions of identical, hypoimmune insulin-producing cells to be manufactured for clinical use.

If successful, this approach could do more than just improve treatment—it could pave the way toward an actual cure. Carlsson believes these engineered stem cells could eventually become the foundation of a pharmaceutical product capable of replacing insulin injections entirely.

In the world of diabetes care, where day-to-day management has long been the norm, this study offers a radical alternative: reprogramming the body to do what it once could—without compromise, and without fear of immune rejection.

[Source: 1,2]

The post New Diabetes Treatment Uses Genetically Modified Cells to Avoid Immune Rejection appeared first on Medical Journal Daily.

The project, which has been over a decade in the making, centers on creating the right environment for early tooth development. Scientists developed a biomaterial that allows cells to interact just like they would in a developing jaw—something previous attempts hadn’t been able to replicate.

Why It Matters More Than It Sounds

Tooth loss is common, and for many adults, artificial fixes like fillings or implants are the only option—at least for now. Fillings can break down over time and sometimes make the surrounding tooth weaker. Implants, while more durable, involve invasive surgery and don’t always fuse perfectly with the jawbone.

But this new approach could change that. Instead of inserting a synthetic object, scientists could use a patient’s own cells to grow a fully functioning tooth. One that integrates into the jaw, responds to pressure, and even continues to develop like a natural tooth would.

Xuechen Zhang, a researcher involved in the project, explained the difference: “Fillings and implants are mechanical solutions. They fix the damage, but they don’t restore the biology. We’re looking at how to actually regrow the tissue—something that could last longer and behave like the real thing.”

The Science Behind Lab Grown Human Teeth

The key to this research was developing a material that mimics the “matrix” surrounding cells during early tooth development. In past attempts, scientists tried to grow teeth by flooding cells with signals all at once. That didn’t work—cells couldn’t organize properly or form structure.

This time, the new custom-engineered material released those same signals slowly, allowing cells to communicate and differentiate at their own pace.

Once the team saw that cells were beginning to form tooth-like structures, it confirmed they’d recreated the right developmental environment for the first time.

Two Ways to Grow Teeth from Cells

Now that early-stage development has been achieved in the lab, the next challenge is figuring out how to get those teeth into patients’ mouths.

Researchers are exploring two main methods:

Grow the tooth in the mouth – They could transplant immature tooth cells directly into the jaw and let the tooth form naturally in place.

Grow the tooth in the lab – They could grow a complete tooth outside the body and surgically implant it once it’s mature.

Both options start with the same lab-based process, but each offers different benefits. One minimizes lab handling; the other gives scientists more control over how the tooth forms.

A Step Toward Regenerative Dentistry

This work is part of a growing trend in regenerative medicine, where the goal is to heal or rebuild the body using its own biology—no metal, no plastics. In the dental world, that means moving away from mechanical repairs and toward true tissue regeneration.

Dr. Ana Angelova-Volponi, who leads the regenerative dentistry program at King’s, says this shift could eventually redefine how dentists treat tooth loss: “Instead of just filling gaps, we could restore real function. That’s the difference.”

The research is still in its early stages, and clinical use is likely years away. But the foundation is now in place. For the first time, growing a human tooth from scratch is more than just a theory—it’s a working process.

[Source]

The post Scientists Grow Human Teeth in Lab appeared first on Medical Journal Daily.

Diagnosed with Mayer-Rokitansky-Küster-Hauser (MRKH) syndrome, a rare condition that left her without a functioning uterus, Grace had long been told pregnancy wasn’t an option. But in 2023, she received a womb from her sister Amy, and within months, she became pregnant through IVF. Her daughter, born on February 27, 2025, represents more than a personal milestone—it’s a significant advance in reproductive medicine.

The womb transplant birth is not just a medical success story. It gives hope to thousands of women living with uterine factor infertility (UFI), especially those with MRKH syndrome. In the UK, about 15,000 women of reproductive age are affected, including roughly 5,000 who are born without a uterus.

Surgery, Science, and Sisterhood

In Oxford, a team of over 30 medical staff carried out a 17-hour operation to remove Amy Purdie’s uterus and transplant it into her younger sister. The sisters had spent years navigating options like surrogacy and adoption, but Grace wanted the chance to carry a child herself. She had always felt a “mothering instinct,” she said—something difficult to suppress, and even harder to let go of.

Grace’s pregnancy progressed well, with IVF successful on the first attempt. She experienced her first period within two weeks of the transplant—a crucial sign that the donor organ had integrated successfully.

When baby Amy arrived slightly early at 4.5 pounds via a planned Caesarean section, both parents were present, along with several members of the transplant and fertility teams. The baby’s full name, Amy Isabel, honors her aunt and the lead surgeon, Isabel Quiroga, who spearheaded the operation at Churchill Hospital.

Interestingly, Grace will eventually have the transplanted womb removed—likely after a second child. The reason is to reduce long-term health risks associated with daily immunosuppressants, which are necessary to prevent organ rejection but can increase the risk of cancer over time.

A Global and Growing Field

While this was the first successful womb transplant birth in the UK, the global field is steadily expanding. Since Sweden reported the first successful birth from a womb transplant in 2014, around 135 procedures have taken place in countries such as the US, China, India, and France. Approximately 65 babies have been born worldwide using this method.

In the UK, Womb Transplant UK has permission to carry out 15 transplants as part of a clinical trial. Grace’s surgery marked the first of its kind, followed by three more transplants using wombs donated after death. Each transplant costs around £30,000 and requires stored embryos before approval. The charity has funding for two more and is actively fundraising to continue.

What sets the UK program apart is its focus on both living and deceased donors. Deceased donor transplants involve additional legal and ethical hurdles, including consent from families. However, they also eliminate risks to a living donor, making them an important avenue for the future.

The Bigger Picture

Medical experts agree that this birth marks a “huge milestone” for reproductive healthcare in the UK. According to Stuart Lavery, consultant at UCLH, the achievement reflects not only scientific progress but also the resolve of patients and medical teams to push boundaries.

Still, womb transplantation is not without challenges. It remains a complex, expensive, and resource-intensive procedure. Long-term data on risks and outcomes are still emerging. Immunosuppressive therapy, surgical risks, and psychological tolls must all be considered. Yet, for women like Grace, the ability to carry and deliver a child is worth the complexity.

Grace and her husband Angus, who described the experience as overwhelming and deeply emotional, hope their story will offer new hope to others. And with baby Amy now safely at home, that hope is no longer theoretical—it’s living and breathing in the arms of her parents.

[Source]

The post UK’s First Baby Born After Womb Transplant appeared first on Medical Journal Daily.